Remarkable Immunotherapy Success in Advanced Colon Cancer
A 33-year-old man with Lynch syndrome (MSH2 mutation) and metastatic colon cancer achieved a dramatic and sustained response to pembrolizumab after failing multiple standard therapies. His journey underscores the life-changing potential of immunotherapy in MSI-High colorectal cancer
Remarkable Immunotherapy Success in Advanced Colon Cancer Read More »